Halozyme Therapeutics (United States)

Recent papers from Halozyme Therapeutics (United States)

1. rHuPH20 Enhances Extravascular Delivery of mRNA Lipid Nanoparticles in Mice and MinipigsNucleic Acid Therapeutics · 2026
2. Challenging the myths of subcutaneous delivery: An industry expert perspectiveJournal of Controlled Release · 2026
3. Enhanced subcutaneous delivery of antibody-drug conjugates with recombinant human hyaluronidase PH20: pharmacokinetics and tolerability in minipigsDrug Delivery and Translational Research · 2026
4. Translatability of a miniature pig model to predict subcutaneous clinical injection times with a high-volume auto-injector and recombinant human hyaluronidase.2026
5. Quantifying Return on Investment of Differentiating Technologies in Drug Development: A Decision Analytics FrameworkJournal of Pharmaceutical Innovation · 2026
6. REMOVED: Challenging the myths of subcutaneous delivery: An industry expert perspectiveJournal of Controlled Release · 2026
7. Removal of Interstitial Hyaluronan Facilitates Subcutaneous Administration and Lymphatic Delivery of Anti-CTLA4 and Improves Antitumor EfficacyCancer Immunology Research · 2026
8. An industry perspective on clinical development and regulatory strategies for subcutaneously administered high-dose biologicsJournal of Controlled Release · 2025
9. Real-World Quantitative Insights into the Treatment Experience of Patients with Cancer in the USA with Subcutaneous Versus Intravenous Drug DeliveryOncology and Therapy · 2025
10. A phase I clinical study to evaluate rapid, high-volume, subcutaneous auto-injector tolerability with recombinant human hyaluronidaseDrug Delivery and Translational Research · 2025
11. Development and Preclinical Testing of a Rapid, High-Volume, Auto-Injector for Subcutaneous Administration with Recombinant Human HyaluronidaseAAPS PharmSciTech · 2025
12. A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIVClinical Pharmacology in Drug Development · 2025
13. The Impact of Vaccination Frequency on COVID-19 Public Health Outcomes: A Model-Based AnalysisVaccines · 2025
14. Newer formulations of oral testosterone undecanoate: development and liver side effectsSexual Medicine Reviews · 2024
15. Development of in vitro biopharmaceutics tools for predicting the bioavailability of subcutaneously injected monoclonal antibodies and oligonucleotidesExpert Opinion on Drug Delivery · 2024
16. Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11Molecular Cancer Therapeutics · 2024
17. Demonstration of Physicochemical and Functional Similarity of Biosimilar Pegfilgrastim-cbqv to PegfilgrastimDrugs in R&D · 2024
18. Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery designAdvanced Drug Delivery Reviews · 2024
19. Modeling the subcutaneous pharmacokinetics of antibodies co‐administered with rHuPH20Clinical and Translational Science · 2024
20. Identifying a predictive relationship between maximal flow rate and viscosity for subcutaneous administration of macromolecules with recombinant human hyaluronidase PH20 in a miniature pig modelDrug Delivery · 2023